Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:ABT-737
go back to main search page
Accession:CHEBI:47575 term browser browse the term
Definition:A biphenyl that is 4-chloro-1,1'-biphenyl substituted by a (4-{4-[(4-{[(2R)-4-(dimethylamino)-1-(phenylsulfanyl)butan-2-yl]amino}-3-nitrobenzene-1-sulfonyl)carbamoyl]phenyl}piperazin-1-yl)methyl group at position 2'. It is a BH3-mimetic drug which targets the anti-apoptotic B-cell lymphoma-2 (BCL-2) family proteins, including BCL-2, BCL-xL, and BCL-w, and induces apoptosis in cancer cells.
Synonyms:exact_synonym: 4-{4-[(4'-chloro[biphenyl]-2-yl)methyl]piperazin-1-yl}-N-[(4-{[(2R)-4-(dimethylamino)-1-(phenylsulfanyl)butan-2-yl]amino}-3-nitrophenyl)sulfonyl]benzamide
 related_synonym: 4-{4-[(4'-chloro[1,1'-biphenyl]-2-yl)methyl]piperazin-1-yl}-N-(4-{[(2R)-4-(dimethylamino)-1-(phenylsulfanyl)butan-2-yl]amino}-3-nitrobenzene-1-sulfonyl)benzamide;   ABT737;   Formula=C42H45ClN6O5S2;   InChI=1S/C42H45ClN6O5S2/c1-46(2)23-22-35(30-55-37-9-4-3-5-10-37)44-40-21-20-38(28-41(40)49(51)52)56(53,54)45-42(50)32-14-18-36(19-15-32)48-26-24-47(25-27-48)29-33-8-6-7-11-39(33)31-12-16-34(43)17-13-31/h3-21,28,35,44H,22-27,29-30H2,1-2H3,(H,45,50)/t35-/m1/s1;   InChIKey=HPLNQCPCUACXLM-PGUFJCEWSA-N;   SMILES=CN(C)CC[C@H](CSC1=CC=CC=C1)NC1=C(C=C(C=C1)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC2=CC=CC=C2C2=CC=C(Cl)C=C2)CC1)[N+]([O-])=O
 xref: CAS:852808-04-9;   Chemspider:9403232;   LINCS:LSM-1180
 xref_mesh: MESH:C501332
 xref: PDBeChem:N3C;   PMID:17572662;   PMID:26880588;   PMID:29543705;   PMID:29792865;   PMID:29856968;   PMID:30389373;   PMID:30402442;   PMID:30557204;   PMID:30625226;   PMID:30721730;   PMID:31493778;   PMID:31579427;   PMID:31612056;   PMID:31906234;   PMID:32079453;   PMID:32083466;   PMID:32139422;   PMID:32212793;   PMID:32424251;   PMID:32470451;   PMID:32580291;   PMID:32623836;   PMID:32811502;   PMID:32966375;   PMID:33140666;   PMID:33218059;   PMID:33396645;   PMID:33523649;   PMID:33786632;   PMID:33787344;   Wikipedia:ABT-737


show annotations for term's descendants           Sort by:
 
ABT-737 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bag3 BAG cochaperone 3 decreases response to substance
multiple interactions
ISO BAG3 protein results in decreased susceptibility to ABT-737
[BAG3 protein results in increased stability of MCL1 protein] which results in decreased susceptibility to ABT-737; BAG3 mutant form inhibits the reaction [MCL1 protein results in decreased susceptibility to ABT-737]
CTD PMID:23341456 NCBI chr 1:199,941,258...199,965,191
Ensembl chr 1:199,941,161...199,965,191
JBrowse link
G Bax BCL2 associated X, apoptosis regulator affects folding
multiple interactions
ISO ABT-737 affects the folding of BAX protein
[ABT-737 co-treated with Etoposide] affects the folding of and results in increased activity of BAX protein; [ABT-737 inhibits the reaction [BCL2L11 protein binds to BCL2 protein]] promotes the reaction [BCL2L11 protein results in increased activity of BAX protein]; ABT-737 inhibits the reaction [BAX protein binds to BCL2 protein]
CTD PMID:17097560 PMID:17200714 PMID:21880625 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions
decreases response to substance
ISO ABT-737 inhibits the reaction [BCL2 protein results in decreased susceptibility to Valproic Acid]; ABT-737 inhibits the reaction [BCL2 protein results in decreased susceptibility to Vorinostat]
[2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased phosphorylation of BCL2 protein] which results in increased susceptibility to ABT-737; [ABT-737 inhibits the reaction [BCL2L11 protein binds to BCL2 protein]] promotes the reaction [BCL2L11 protein results in increased activity of BAX protein]; [ABT-737 results in decreased activity of BCL2 protein] which results in increased susceptibility to fosbretabulin; [BCL2L11 protein binds to BCL2 protein] which affects the susceptibility to ABT-737; ABT-737 inhibits the reaction [BAX protein binds to BCL2 protein]; ABT-737 inhibits the reaction [BCL2L11 protein binds to BCL2 protein]; ABT-737 inhibits the reaction [Silicon Dioxide promotes the reaction [BCL2 protein binds to BECN1 protein]]; BCL2 protein inhibits the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]]; BCL2 protein inhibits the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]]
BCL2 protein modified form results in decreased susceptibility to ABT-737
CTD PMID:17097560 PMID:17200714 PMID:19060243 PMID:20104024 PMID:24321340 PMID:32061152 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions
increases expression
ISO ABT-737 inhibits the reaction [BCL2L1 protein results in decreased susceptibility to Valproic Acid]; ABT-737 inhibits the reaction [BCL2L1 protein results in decreased susceptibility to Vorinostat]
ABT-737 inhibits the reaction [Cholecalciferol promotes the reaction [BECN1 protein binds to BCL2L1 protein]]
ABT-737 results in increased expression of BCL2L1 protein alternative form
CTD PMID:18628207 PMID:19060243 PMID:21256112 NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
JBrowse link
G Bcl2l11 BCL2 like 11 multiple interactions
increases response to substance
ISO [ABT-737 inhibits the reaction [BCL2L11 protein binds to BCL2 protein]] promotes the reaction [BCL2L11 protein results in increased activity of BAX protein]; [BCL2L11 protein binds to BCL2 protein] which affects the susceptibility to ABT-737; [MCL1 protein results in decreased activity of BCL2L11 protein] which results in decreased susceptibility to ABT-737; ABT-737 inhibits the reaction [BCL2L11 protein binds to BCL2 protein]
BCL2L11 protein results in increased susceptibility to ABT-737
CTD PMID:17097560 PMID:17200714 PMID:20038611 PMID:23341456 NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
JBrowse link
G Becn1 beclin 1 multiple interactions ISO ABT-737 inhibits the reaction [Cholecalciferol promotes the reaction [BECN1 protein binds to BCL2L1 protein]]; ABT-737 inhibits the reaction [Silicon Dioxide promotes the reaction [BCL2 protein binds to BECN1 protein]] CTD PMID:18628207 PMID:32061152 NCBI chr10:89,209,944...89,225,297
Ensembl chr10:89,209,940...89,225,297
JBrowse link
G Bid BH3 interacting domain death agonist multiple interactions ISO [ABT-737 co-treated with Celecoxib] results in increased cleavage of BID protein CTD PMID:20104024 NCBI chr 4:153,439,812...153,465,247
Ensembl chr 4:153,442,218...153,465,203
JBrowse link
G Braf B-Raf proto-oncogene, serine/threonine kinase multiple interactions ISO ABT-737 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]] CTD PMID:27689874 NCBI chr 4:67,389,331...67,520,549
Ensembl chr 4:67,396,192...67,520,356
JBrowse link
G Casp3 caspase 3 increases cleavage
multiple interactions
increases activity
ISO ABT-737 results in increased cleavage of CASP3 protein
3-methyladenine promotes the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]]; 3-methyladenine promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]; 3-methyladenine promotes the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]]; [ABT-737 co-treated with Celecoxib] results in increased activity of CASP3 protein; [Quercetin results in increased susceptibility to ABT-737] which results in increased activity of CASP3 protein; ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]; ABT-737 promotes the reaction [Wortmannin promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]]; BCL2 protein inhibits the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]]; BCL2 protein inhibits the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [3-methyladenine promotes the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [3-methyladenine promotes the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]]; Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]; MAP1LC3B mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP3 protein]; PIK3C3 mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP3 protein]
ABT-737 results in increased activity of CASP3 protein
CTD PMID:19010845 PMID:19773376 PMID:20038611 PMID:20104024 PMID:23353698 PMID:23918355 PMID:30461186 PMID:33662508 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp7 caspase 7 increases activity ISO ABT-737 results in increased activity of CASP7 protein CTD PMID:20038611 NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
JBrowse link
G Casp8 caspase 8 increases cleavage
multiple interactions
ISO ABT-737 results in increased cleavage of CASP8 protein
3-methyladenine promotes the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP8 protein]]; 3-methyladenine promotes the reaction [ABT-737 results in increased cleavage of CASP8 protein]; 3-methyladenine promotes the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP8 protein]]; [ABT-737 co-treated with Celecoxib] results in increased activity of CASP8 protein; ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP8 protein]; ABT-737 promotes the reaction [Wortmannin promotes the reaction [Celecoxib results in increased cleavage of CASP8 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [3-methyladenine promotes the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP8 protein]]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [3-methyladenine promotes the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP8 protein]]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP8 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP8 protein]]; Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP8 protein]; MAP1LC3B mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP8 protein]; PIK3C3 mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP8 protein]
CTD PMID:20104024 NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
JBrowse link
G Casp9 caspase 9 increases activity
increases cleavage
multiple interactions
ISO ABT-737 results in increased activity of CASP9 protein
ABT-737 results in increased cleavage of CASP9 protein
3-methyladenine promotes the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP9 protein]]; 3-methyladenine promotes the reaction [ABT-737 results in increased cleavage of CASP9 protein]; 3-methyladenine promotes the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP9 protein]]; [ABT-737 co-treated with Celecoxib] results in increased activity of CASP9 protein; [Quercetin results in increased susceptibility to ABT-737] which results in increased activity of CASP9 protein; ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP9 protein]; ABT-737 promotes the reaction [Wortmannin promotes the reaction [Celecoxib results in increased cleavage of CASP9 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [3-methyladenine promotes the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP9 protein]]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [3-methyladenine promotes the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP9 protein]]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP9 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP9 protein]]; Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP9 protein]; MAP1LC3B mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP9 protein]; PIK3C3 mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP9 protein]
CTD PMID:20104024 PMID:23353698 PMID:30461186 PMID:33662508 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
JBrowse link
G Hgf hepatocyte growth factor multiple interactions ISO ABT-737 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]] CTD PMID:27689874 NCBI chr 4:15,435,460...15,505,377
Ensembl chr 4:15,433,295...15,505,362
JBrowse link
G Krt18 keratin 18 increases cleavage ISO ABT-737 results in increased cleavage of KRT18 protein CTD PMID:19010845 NCBI chr 7:143,629,455...143,633,131
Ensembl chr 7:143,629,455...143,633,131
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO MAP1LC3B mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP3 protein]; MAP1LC3B mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP8 protein]; MAP1LC3B mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP9 protein] CTD PMID:20104024 NCBI chr19:53,635,449...53,643,970
Ensembl chr19:53,629,779...53,646,058
JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member decreases response to substance
multiple interactions
ISO MCL1 protein results in decreased susceptibility to ABT-737
[BAG3 protein results in increased stability of MCL1 protein] which results in decreased susceptibility to ABT-737; [Cycloheximide co-treated with MCL1] results in increased susceptibility to ABT-737; [MCL1 protein results in decreased activity of BCL2L11 protein] which results in decreased susceptibility to ABT-737; BAG3 mutant form inhibits the reaction [MCL1 protein results in decreased susceptibility to ABT-737]
CTD PMID:17097560 PMID:17688235 PMID:21880625 PMID:23341456 NCBI chr 2:197,786,212...197,788,992 JBrowse link
G Met MET proto-oncogene, receptor tyrosine kinase multiple interactions ISO ABT-737 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]] CTD PMID:27689874 NCBI chr 4:44,747,467...44,854,628
Ensembl chr 4:44,774,741...44,852,665
JBrowse link
G Mki67 marker of proliferation Ki-67 multiple interactions
decreases expression
ISO [ABT-737 co-treated with Sirolimus] results in decreased expression of MKI67 protein
ABT-737 results in decreased expression of MKI67 protein
CTD PMID:19773376 NCBI chr 1:207,993,895...208,020,454
Ensembl chr 1:207,993,895...208,020,454
JBrowse link
G Nanog Nanog homeobox decreases expression ISO ABT-737 results in decreased expression of NANOG protein CTD PMID:23918355 NCBI chr 4:155,531,906...155,539,268
Ensembl chr 4:155,531,906...155,539,268
JBrowse link
G Pik3c3 phosphatidylinositol 3-kinase, catalytic subunit type 3 multiple interactions ISO PIK3C3 mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP3 protein]; PIK3C3 mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP8 protein]; PIK3C3 mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP9 protein] CTD PMID:20104024 NCBI chr18:22,964,121...23,047,896
Ensembl chr18:22,964,210...23,047,895
JBrowse link
G Pmaip1 phorbol-12-myristate-13-acetate-induced protein 1 increases response to substance ISO PMAIP1 protein results in increased susceptibility to ABT-737 CTD PMID:17688235 NCBI chr18:62,159,128...62,179,635
Ensembl chr18:62,174,670...62,181,102
JBrowse link
G Rassf1 Ras association domain family member 1 multiple interactions ISO ABT-737 promotes the reaction [RASSF1 results in increased susceptibility to Cisplatin]; ABT-737 promotes the reaction [RASSF1 results in increased susceptibility to Etoposide] CTD PMID:21880625 NCBI chr 8:116,307,149...116,318,289
Ensembl chr 8:116,307,141...116,318,289
JBrowse link
G Sqstm1 sequestosome 1 multiple interactions ISO [Celecoxib co-treated with ABT-737] results in decreased expression of SQSTM1 protein; ABT-737 promotes the reaction [Silicon Dioxide results in decreased expression of SQSTM1 protein] CTD PMID:20104024 PMID:32061152 NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19773
    role 19719
      application 19403
        anti-inflammatory agent 15766
          ABT-737 23
Path 2
Term Annotations click to browse term
  CHEBI ontology 19773
    subatomic particle 19772
      composite particle 19772
        hadron 19772
          baryon 19772
            nucleon 19772
              atomic nucleus 19772
                atom 19772
                  main group element atom 19662
                    main group molecular entity 19662
                      s-block molecular entity 19426
                        hydrogen molecular entity 19420
                          hydrides 18753
                            inorganic hydride 17457
                              pnictogen hydride 17433
                                nitrogen hydride 17280
                                  azane 17015
                                    ammonia 17014
                                      organic amino compound 17013
                                        tertiary amino compound 8671
                                          N-arylpiperazine 2766
                                            ABT-737 23
paths to the root